Patient and Physician Perspectives on Biosimilar Use
The perspectives of patients and physicians play a pivotal role in the acceptance and integration of biosimilars into everyday clinical practice. Despite strong regulatory assurances of biosimilarity in terms of safety, efficacy, and quality, perceptions and confidence levels among healthcare providers and patients significantly influence prescribing behaviors, switching decisions, and overall market uptake. For physicians, biosimilars represent an opportunity to offer cost-effective treatment options, expand patient access, and optimize healthcare resources. However, concerns often linger regarding the clinical equivalence of biosimilars, especially in complex therapeutic areas such as oncology, rheumatology, and immunology. Many clinicians express caution about switching stable patients from originator biologics to biosimilars, largely due to a lack of long-term real-world data, fears about immunogenicity, or the perception that even minor structural differences might impact clinical outcomes. These concerns are particularly evident in regions where biosimilars are newly introduced, or where regulatory guidance on interchangeability and substitution is limited or inconsistent. Physicians’ willingness to prescribe biosimilars is heavily influenced by their level of education and experience with these products. Continuing medical education, access to comparative data, and positive clinical experiences can help shift attitudes from skepticism to acceptance. Endorsement by professional societies and inclusion of biosimilars in clinical guidelines also provide reassurance and promote wider adoption.
Related Conference of Patient and Physician Perspectives on Biosimilar Use
20th World Congress on Biomarkers, Cancer Therapy & Clinical Research
7th Annual Congress on Biosimilars and Future Biotherapeutics
41st International Conference on Next-Gen Biotechnology and Applications
Patient and Physician Perspectives on Biosimilar Use Conference Speakers
Recommended Sessions
- Advancements in Biosimilar Development Technologies
- Artificial Intelligence and Digital Tools in Biotherapeutics
- Biobetters: The Next Generation of Biologics
- Biosimilar Market Access and Reimbursement Policies
- Biosimilars in Oncology and Autoimmune Diseases
- Biosimilars in Rare and Orphan Diseases
- Clinical Trials & Comparability Studies for Biosimilars
- Collaborative Models in Biosimilar Development
- Cost-Effectiveness and Health Economics of Biosimilars
- Evolving Trends and Innovations in Biosimilar Development and Access
- Formulation and Delivery Systems for Biologics
- Future Biotherapeutics: Cell and Gene Therapies
- Future of Monoclonal Antibodies and Fusion Proteins
- Global Trends and Challenges in Biosimilar Adoption
- Immunogenicity Assessment and Risk Management
- Interchangeability and Substitution Policies
- Manufacturing and Quality Control of Biosimilars
- Patient and Physician Perspectives on Biosimilar Use
- Pharmacovigilance and Post-Marketing Surveillance
- Regulatory Pathways and Global Harmonization
Related Journals
Are you interested in
- 3D Bioprinting & Regenerative Medicine - Biotechnology- 2025 (France)
- Advancements in Analytical Techniques - ANALYTICA ACTA 2025 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- AI in Drug Discovery - Biotechnology- 2025 (France)
- AI in Vaccine Development - Biotechnology- 2025 (France)
- AI-Powered Precision Medicine - Biotechnology- 2025 (France)
- Analytical Challenges in Personalized Medicine - ANALYTICA ACTA 2025 (France)
- Analytical Chemistry in Agriculture - ANALYTICA ACTA 2025 (France)
- Analytical Chemistry in the Energy Sector - ANALYTICA ACTA 2025 (France)
- Analytical Techniques for Biotechnology - ANALYTICA ACTA 2025 (France)
- Analytical Techniques in Material Science - ANALYTICA ACTA 2025 (France)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Automation in Bioanalytical Laboratories - ANALYTICA ACTA 2025 (France)
- Bio-Cybernetics & Smart Implants - Biotechnology- 2025 (France)
- Bioanalytical Method Development and Validation - ANALYTICA ACTA 2025 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioethics in Biotechnology 5.0 - Biotechnology- 2025 (France)
- Bioinformatics & Big Data - Biotechnology- 2025 (France)
- Bioinformatics and Computational Approaches - ANALYTICA ACTA 2025 (France)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biopharmaceuticals and Biologics - ANALYTICA ACTA 2025 (France)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Space - Biotechnology- 2025 (France)
- Blockchain for Biotech Data Security - Biotechnology- 2025 (France)
- Brain-Computer Interfaces & Neurobiotech - Biotechnology- 2025 (France)
- Chemical Analysis and Sensing - ANALYTICA ACTA 2025 (France)
- Clinical and Forensic Analysis - ANALYTICA ACTA 2025 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- CRISPR & Beyond - Biotechnology- 2025 (France)
- Data Integrity and Compliance in Analytical Chemistry - ANALYTICA ACTA 2025 (France)
- Emerging Contaminants and Analytical Challenges - ANALYTICA ACTA 2025 (France)
- Emerging Trends in Analytical and Bioanalytical Techniques - ANALYTICA ACTA 2025 (France)
- Environmental Analysis - ANALYTICA ACTA 2025 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Food and Beverage Analysis - ANALYTICA ACTA 2025 (France)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of AgriTech - Biotechnology- 2025 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Genomics and Molecular Biology Analysis - ANALYTICA ACTA 2025 (France)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- High-Resolution Techniques - ANALYTICA ACTA 2025 (France)
- Imaging Techniques and Microscopy - ANALYTICA ACTA 2025 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial Biotech & Smart Biofactories - Biotechnology- 2025 (France)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Instrumentation and Automation in Analytical Chemistry - ANALYTICA ACTA 2025 (France)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Metabolomics and Proteomics - ANALYTICA ACTA 2025 (France)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nanomaterials and Nanotechnology in Analysis - ANALYTICA ACTA 2025 (France)
- Nanotechnology in Medicine - Biotechnology- 2025 (France)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Personalized Nutrition & Gut Microbiome - Biotechnology- 2025 (France)
- Pharmaceutical Analysis - ANALYTICA ACTA 2025 (France)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Quality by Design (QbD) in Analytical Method Development - ANALYTICA ACTA 2025 (France)
- Quantum Computing in Biotech - Biotechnology- 2025 (France)
- Regenerative Medicine and Analytical Techniques - ANALYTICA ACTA 2025 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Smart Biomanufacturing - Biotechnology- 2025 (France)
- Spectroscopic Techniques - ANALYTICA ACTA 2025 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Surface and Interface Analysis - ANALYTICA ACTA 2025 (France)
- Sustainable Biotech Innovations - Biotechnology- 2025 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Synthetic Biology: Reprogramming Life - Biotechnology- 2025 (France)
- The Future of Biotech Startups - Biotechnology- 2025 (France)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)
- Workshops and Hands-On Training - ANALYTICA ACTA 2025 (France)